Securities code: 002980 securities abbreviation: Shenzhen Everbest Machinery Industry Co.Ltd(002980)
Shenzhen Everbest Machinery Industry Co.Ltd(002980)
Record of investor relations activities
No.: 2022-001
√ specific object research □ analyst meeting
Investor relations activities □ media interviews □ performance briefing
Category □ press conference □ roadshow activity
□ site visit
□ others (please describe other activities in words)
Name and of participant
China Post Fund: Jin Zhenzhen
Personnel name
Time: January 6, 2022
Place: company conference room
Receptionist of listed company, Secretary of the board of directors: Ren Huan
Name of securities representative: Hu Xiaoyu
1、 Company profile
The company was established on March 26, 1991 and listed on Shenzhen Stock Exchange on April 15, 2020.
Since its establishment 30 years ago, the investor relations activity company has been deeply engaged in the technology of instrument measurement and testing industry, mainly introducing R & D and product manufacturing. It has rich experience in product R & D and extensive technical reserves, and has mastered the core measurement and testing technologies in the fields of power, electronics, electrician, environment, medical treatment, construction, automobile, infrared and so on, It covers the parameter measurement of various electric quantity, mechanical quantity, thermal quantity, chemical quantity, acoustic quantity, optical quantity and radioactive quantity. The downstream application industries of the products include power electrician, electronic manufacturing, petrochemical industry, steel smelting, HVAC, building surveying and mapping, rail transit, warehousing and transportation, environmental monitoring, medical health, automobile maintenance, Internet of things, etc. As a leading comprehensive measurement and testing solution expert in China, the company has professional, customized and one-stop product R & D and production capacity, continues to carry out product innovation and lead the development of the industry. It is one of the comprehensive measurement and testing instrument enterprises with the strongest product innovation ability and the richest product categories in China. From January 1, 2021 to September 30, 2021, the company realized an operating revenue of 55.173 million yuan and a net profit attributable to shareholders of listed companies of 130.72 million yuan, of which the sales revenue of non epidemic prevention products increased by 39.66% over the same period of last year, 52.75% over the same period of 2019 before the epidemic, and the overall operating revenue of the company increased by 61.80% over the same period of 2019 before the epidemic, The net profit attributable to shareholders of listed companies increased by 77.21% over the same period in 2019. The average gross profit margin of the company’s products is 40.66% and the net profit margin is 23.70%. The company has good profitability.
2、 Interactive communication link
1. Reasons and progress of the company’s construction of ” Shenzhen Everbest Machinery Industry Co.Ltd(002980) intelligent sensor measuring instrument R & D and production project” in Huizhou
A: the company’s “R & D and production project of Shenzhen Everbest Machinery Industry Co.Ltd(002980) intelligent sensor measuring instrument” in Huizhou is a plan made in combination with the company’s current production and operation and future development needs. After the completion of the project, it can expand the production capacity, optimize the company’s industrial structure, improve the industrial layout and further enhance the company’s comprehensive competitiveness, Promote the rapid development of intelligent sensing measurement and detection business and other new businesses.
At present, the company has registered a wholly-owned subsidiary in Tonghu ecological wisdom zone, Huizhou, and successfully won the state-owned construction land use right of plot No. gzk2021-115 in the middle of international cooperation Industrial Park, Tonghu ecological wisdom zone, Zhongkai high tech Zone, Huizhou as the construction land of the project. Subsequently, the company will actively promote the implementation of matters related to the construction of the project.
2. Layout and progress of the company in the field of medical testing
A: with advanced infrared temperature measurement technology, the company has developed a series of non-contact infrared human body temperature measurement products. Human body temperature measurement products have sold more than millions of units. With strong R & D strength and many years of market operation, the company has accumulated a large number of medical customer resources and medical device product R & D and production experience.
The company has successfully developed real-time fluorescence quantitative PCR analyzer, and has obtained EU CE certification and UK MHRA registration. The product has the characteristics of small volume, fast response, easy operation, safety and portability. It is equipped with 4-channel multiple fluorescence detection, which can detect 16 samples at a time; The test process is deeply customized according to the user’s habits. After the PCR experiment is completed, the report can be automatically sent and stored, and remote data sharing can be realized; In the field of nucleic acid detection, it can be adapted to most nucleic acid reagents on the market to detect a variety of pathogens and gene targets. It can be widely used in hospital POCT, CDC, customs, Airport Quarantine, grass-roots medical institutions, mobile laboratories, field emergency detection, animal quarantine, food safety and scientific teaching and research; It is one of the company’s important products in the field of IVD in vitro diagnosis. The real-time fluorescence quantitative PCR analyzer developed by the company in cooperation with leading reagent enterprises and tested with its reagent, with excellent performance.
The company has established a biomedical laboratory, strengthened the construction of professional teams in biology and medicine, plans to establish multiple technical platforms such as molecular diagnosis, POCT rapid detection and chronic disease management, and plans to prepare R & D and production laboratories and production lines for antigen and antibody reagents. Adhering to the concept of “forge ahead and collaborative innovation”, the company will continue to optimize the existing products and medical industry, and form a development layout from life medicine, public health to family health, based on molecular diagnosis technology, to POCT and chronic disease management radiation.
3. MEMS sensor and its market application
A: during the epidemic, there was a huge demand for infrared thermometers, and the products were in short supply. With years of accumulation of infrared thermometry technology, the company developed chip level MEMS infrared thermometers. The sensor has the product characteristics of ultra-small volume, low cost, high integration, low energy consumption and digital output, solves the “neck” technical bottleneck and brings upgrading to the infrared temperature measurement industry.
With the development of information technology, sensing technology, as one of the three pillars of information technology, has broad development prospects. At present, MEMS sensors and various measurement sensor modules are developing rapidly. The company has accumulated measurement technology and sensor technology for 30 years in the application of sensors, has conducted in-depth research on various measurement sensors, and is fully capable of independently developing front-end core technology sensors. The company will Increase R & D investment in module and application industry chain technology. It is expected that there will be broad market prospects in the Internet of things and consumer electronics industry in the future.
4. About the driving force of the company’s future development
A: according to the data of markets and markets, the market scale of global measurement and test instruments is expected to increase from US $25.7 billion in 2018 to US $32.3 billion in 2024, with broad market prospects. In the first half of this year, domestic business revenue accounted for 11.68%, an increase of 236% compared with 2019 before the epidemic. In recent years, with the support of national policies and the improvement of scientific and technological strength, the technology of instrument industry has developed rapidly, and the technology gap with developed foreign countries such as Europe, America and Japan is becoming smaller and smaller. In some aspects, it has begun to compare with foreign advanced technology. With the expansion of the market scale of the instrument industry, more and more attention is paid to R & D, and human and material resources are actively invested in product R & D. In addition, the price of foreign leading products is high. At the same time, for long-term consideration, many Chinese enterprises actively respond to the call for localization substitution and try and buy high-quality products of Chinese enterprises with strong technical strength and good brand in the industry. In the future, with the gradual formation of the “new development pattern of mutual promotion with China’s international double cycle”, it is expected to further promote the domestic substitution of instruments and meters, Enhance the competitiveness of Chinese enterprises. The company will have the courage to seize the opportunities of the times, actively expand the Chinese market sales team and make better use of China
China’s two markets and two resources will enable the company to reach a new level in the next five years during the 14th Five Year Plan period.
Annex list (if any) none
Date: January 8, 2022
